Amicus Therapeutics Inc

Amicus Therapeutics — Q3 2022 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, Nov 7, 2022

  1. Slide 1: 3Q22 Financial Results Conference Call & Webcast

    3Q22 Financial Results Conference Call & Webcast November 7, 2022 At the Forefront of Therapies for Rare Diseases

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies

  3. Slide 3: A Rare Company

    3 A Rare Company Patient - dedicated, Rare Disease Biotechnology Company with Sustained Double - digit Revenue Growth, a Global Commercial Infrastructure, and Late - stage Development Capabilities AT - GAA a Two - component Therapy Under Global Regulatory Reviews for Pompe Disease GLOBAL COMMERCIAL

  4. Slide 4: Positioned for Significant Value Growth

    4 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double - digit Revenue Growth on Path to Profitability Continue to bring Galafold ® to as many patients as possible, sustain double - digit revenue growth Successful launch of AT - GAA for people living with Pompe

  5. Slide 5: 2022 Strategic Priorities to Drive Value

    2022 Strategic Priorities to Drive Value 1 2 3 4 5 Double - digit Galafold growth (15 - 20%) with revenue of $350M to $365M at CER 1 Secure FDA approval and positive CHMP opinion for AT - GAA Initiate successful, rapid launch in U.S. for AT - GAA Advance best - in - class, next - generation genetic

  6. Slide 6: Galafold (migalastat) Continued Growth

    6 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease

  7. Slide 7: Galafold Success (as of September 30, 2022)

    7 Galafold Success (as of September 30, 2022) Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse re actions reported with Galafold (≥

  8. Slide 8: Galafold Performance YTD

    8 Galafold Performance YTD Reported Revenue Growth of +7.9% to $241.0M – Strong Operational Growth of +16.2% at CER ▪ Global demand remains strong: 3 - month net new patients trend best in 2 years ▪ Call volume increasing from same period last year ▪ Global mix of switch (~55%) and previously untrea

  9. Slide 9: Galafold Success and FY22 Revenue Guidance

    9 Galafold Success and FY22 Revenue Guidance Galafold Momentum on Track to Achieve Full - year 2022 Revenue Guidance at CER FY16 FY17 FY18 FY19 FY20 FY21 FY22 $5.0M Q1 $78.7M Q2 $80.7M Q3 $81.6M $36.9M $91.2M $182.2M $260.9M $305.5M 1 2022 Galafold revenue guidance utilizes the average actual rates

  10. Slide 10: Galafold Growth Opportunity

    10 Penetration of the diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong IP rights, including COM protection through 2038 Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual

  11. Slide 11: AT-GAA Launch Preparations

    11 AT - GAA Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease treatment centers Development of educational materials

  12. Slide 12: AT-GAA (cipaglucosidase alfa + miglustat)

    12 AT - GAA ( cipaglucosidase alfa + miglustat ) … potential to establish a new standard of care for people living with Pompe disease

  13. Slide 13: Pompe Disease Overview

    13 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc

  14. Slide 14: Phase 3 PROPEL Study Results

    14 Phase 3 PROPEL Study Results Overall Population (n=122*) Primary and First Key Secondary Endpoint Showed Greater Improvement with AT - GAA vs. alglucosidase alfa in the Overall Population of ERT - Naïve and ERT - Experienced Patients 6MWD=6 - minute walk distance;; FVC=forced vital capacity; SE=s

  15. Slide 15: Long-Term Data from Phase 1/2 Clinical Study (ATB200-02)

    15 Long - Term Data from Phase 1/2 Clinical Study (ATB200 - 02) Persistent and Durable Improvements in Motor and Respiratory Function and Reductions in Biomarkers of Muscle Damage and Disease Substrate Observed in Patients out to 48 Months NOTE: * One patient in the ERT - naïve cohort experienced a

  16. Slide 16: AT-GAA: Ongoing Evidence Generation

    16 AT - GAA: Ongoing Evidence Generation Indirect Treatment Comparison across Pompe ERT Studies Recently Presented at World Muscle Society 2022 Congress Highlights Potential Clinical Differentiation of AT - GAA 6MWD: Relative effect estimates with 95% credible intervals in base - case scenario - 100

  17. Slide 17: AT-GAA: Key Takeaways

    17 AT - GAA: Key Takeaways ▪ U.S. Regulatory status update: – PDUFA action date deferred due to Agency‘s inability to conduct manufacturing inspection in China – At the Agency’s direction, the Company has a Type A meeting scheduled to develop plans and logistics for a pre - approval inspection ▪ Int

  18. Slide 18: Amicus Pipeline

    18 INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold ® (migalastat) Fabry Gene Therapy Next - Generation Chaperone POMPE FRANCHISE AT - GAA (cipaglucosidase alfa + miglustat) Pompe Gene Therapy OTHER CLN3 Batten Disease Gene Therapy Next - Generation R

  19. Slide 19: Financial & Operational Strategy

    19 Financial & Operational Strategy … maintaining a strong financial outlook

  20. Slide 20: Q3 2022 Revenue Performance

    20 Q3 2022 Revenue Performance Q3 2022 Reported Revenue Growth of +2.7% to $81.7M resulting from Strong Operational Growth of +13.6% at CER Offset by Negative FX impact of - 10.9% ▪ Significant currency exposure as 63% of Galafold revenue generated outside the U.S. ▪ Applying average October 2022 ex

  21. Slide 21: Q3 2022 Select Financial Results

    21 Q3 2022 Select Financial Results Q3 2022 OpEx Decrease Related to the Reprioritization of the Gene Therapy Portfolio Sep. 30, 2022 (in thousands, except per share data) Sep. 30, 2021 Product Revenue $81,691 $79,545 Cost of Goods Sold 13,436 11,696 R&D Expense 52,970 59,333 SG&A Expense 47,272 46,

  22. Slide 22: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear Strategy to Build Our Business, Advance Our Portfolio, and Achieve Profitability 22 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT - GAA $ 241M YTD revenue, +16.2% YoY Operational Growth 2022 Galafold revenue growth

  23. Slide 23: Appendix

    ? ’ 4\ . e Ja Amicus t AS) Therapeutics Appendix

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Total operating expenses - as reported GAAP $102,095 S 110,248 $381,714 $331,033 Research and development: Share-based

Amicus Therapeutics — Q3 2022 Earnings Presentation on 6ix